ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for AVBP

Stock NameArriVent BioPharma, Inc. Common Stock
TickerAVBP(USD) NASDAQ
TYPECommon Stock
CountryUSA

Show aggregate AVBP holdings

News associated with AVBP

Brokerages Set ArriVent BioPharma, Inc. (NASDAQ:AVBP) Price Target at $39.14
Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) have been given a consensus recommendation of “Buy” by the seven brokerages that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price […] - 2025-08-20 02:08:54
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 4.3% Following Weak Earnings
ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) shares traded down 4.3% during mid-day trading on Tuesday following a weaker than expected earnings announcement. The stock traded as low as $16.11 and last traded at $16.64. 108,298 shares changed hands during mid-day trading, a decline of 57% from the average session volume of 253,462 shares. […] - 2025-08-14 02:38:57
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of “Buy” from Analysts
Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) have been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 […] - 2025-07-23 04:07:02
Alps Advisors Inc. Decreases Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Alps Advisors Inc. trimmed its position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) by 7.7% during the 1st quarter, Holdings Channel reports. The fund owned 25,167 shares of the company’s stock after selling 2,085 shares during the period. Alps Advisors Inc.’s holdings in ArriVent BioPharma were worth $465,000 at the end of […] - 2025-07-15 06:59:52
Analysts Set ArriVent BioPharma, Inc. (NASDAQ:AVBP) Price Target at $40.00
ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price […] - 2025-07-01 03:07:00
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up After Analyst Upgrade
ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) gapped up before the market opened on Tuesday after Oppenheimer raised their price target on the stock from $39.00 to $44.00. The stock had previously closed at $22.80, but opened at $24.03. Oppenheimer currently has an outperform rating on the stock. ArriVent BioPharma shares last traded at […] - 2025-06-25 02:22:48
Peek Under The Hood: FHLC Has 21% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-20 08:15:40
California State Teachers Retirement System Has $364,000 Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
California State Teachers Retirement System increased its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) by 561.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 13,649 shares of the company’s stock after purchasing an additional 11,585 shares during the period. California State Teachers Retirement System’s […] - 2025-06-12 04:52:48
Brokerages Set ArriVent BioPharma, Inc. (NASDAQ:AVBP) PT at $39.29
ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price […] - 2025-06-06 02:04:58
Millennium Management LLC Sells 164,085 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Millennium Management LLC lessened its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) by 75.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,545 shares of the company’s stock after selling 164,085 shares during the quarter. Millennium Management LLC’s holdings in ArriVent […] - 2025-06-04 04:44:52
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $456,000 Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) by 8.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,114 shares of the company’s stock after buying an additional 1,327 […] - 2025-05-30 04:36:52
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated by Analysts at Jones Trading
Analysts at Jones Trading assumed coverage on shares of ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $40.00 price target on the stock. Jones Trading’s price objective would indicate a potential upside of 95.41% from the company’s previous close. AVBP has […] - 2025-05-22 03:12:44
HC Wainwright Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $40.00
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) had its target price hoisted by analysts at HC Wainwright from $39.00 to $40.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 107.90% from the stock’s previous close. HC […] - 2025-05-16 05:18:53
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives $39.00 Average Price Target from Analysts
Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) have been given an average rating of “Buy” by the six brokerages that are covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year […] - 2025-05-12 02:24:54
MetLife Investment Management LLC Purchases 1,110 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)
MetLife Investment Management LLC increased its position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) by 6.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,460 shares of the company’s stock after buying an additional 1,110 shares during the […] - 2025-05-06 05:08:51
Wells Fargo & Company MN Buys 4,139 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Wells Fargo & Company MN raised its position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) by 40.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,493 shares of the company’s stock after acquiring an additional 4,139 shares during […] - 2025-05-05 04:23:04
Legal & General Group Plc Raises Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Legal & General Group Plc grew its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) by 379.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 13,627 shares of the company’s stock after purchasing an additional 10,783 shares during the quarter. Legal & General Group Plc’s holdings in ArriVent BioPharma were worth […] - 2025-05-01 05:19:07
Wellington Management Group LLP Makes New $1.12 Million Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Wellington Management Group LLP purchased a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) during the fourth quarter, Holdings Channel reports. The fund purchased 41,921 shares of the company’s stock, valued at approximately $1,117,000. Several other hedge funds and other institutional investors also recently made changes to their positions in AVBP. […] - 2025-04-14 05:17:03
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of “Buy” from Brokerages
Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) have been given an average recommendation of “Buy” by the six analysts that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month […] - 2025-04-14 02:10:51
Intech Investment Management LLC Acquires Shares of 14,798 ArriVent BioPharma, Inc. (NASDAQ:AVBP)
Intech Investment Management LLC purchased a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,798 shares of the company’s stock, valued at approximately $394,000. Several other large investors have also recently […] - 2025-03-26 06:20:50
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Buy” by Analysts
ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) has received an average rating of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective […] - 2025-03-25 04:40:43
China Universal Asset Management Co. Ltd. Takes Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)
China Universal Asset Management Co. Ltd. bought a new stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 7,145 shares of the company’s stock, valued at approximately $190,000. Several other hedge funds and other […] - 2025-02-04 06:53:07

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) AVBP holdings

DateNumber of AVBP Shares HeldBase Market Value of AVBP SharesLocal Market Value of AVBP SharesChange in AVBP Shares HeldChange in AVBP Base ValueCurrent Price per AVBP Share HeldPrevious Price per AVBP Share Held
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of AVBP by Blackrock for IE00BYXG2H39

Show aggregate share trades of AVBP

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-06BUY20419.95020.159 20.138USD 4,108 21.61
2025-10-03BUY47619.84020.025 20.006USD 9,523 21.62
2025-10-02BUY6818.83018.940 18.929USD 1,287 21.64
2025-09-30BUY13618.45018.690 18.666USD 2,539 21.67
2025-09-26BUY13618.03018.085 18.079USD 2,459 21.71
2025-09-25BUY13617.17017.750 17.692USD 2,406 21.74
2025-09-24BUY2,21717.86018.510 18.445USD 40,893 21.76
2025-09-18BUY6218.58018.630 18.625USD 1,155 21.78
2025-09-17BUY18617.51018.700 18.581USD 3,456 21.80
2025-09-11SELL-6119.02019.500 19.452USD -1,187 21.87 Profit of 147 on sale
2025-09-10BUY12218.87019.660 19.581USD 2,389 21.88
2025-09-05SELL-6120.19020.450 20.424USD -1,246 21.92 Profit of 91 on sale
2025-08-29SELL-18319.12019.532 19.491USD -3,567 21.98 Profit of 455 on sale
2025-08-27BUY12219.21019.465 19.440USD 2,372 22.01
2025-08-26SELL-6119.59019.745 19.730USD -1,203 22.03 Profit of 140 on sale
2025-08-25BUY6119.35021.190 21.006USD 1,281 22.04
2025-08-20SELL-24419.27019.660 19.621USD -4,788 22.07 Profit of 599 on sale
2025-08-18BUY12219.24019.990 19.915USD 2,430 22.11
2025-08-08SELL-12217.99018.960 18.863USD -2,301 22.25 Profit of 414 on sale
2025-08-05BUY6019.45019.510 19.504USD 1,170 22.32
2025-08-01SELL-18018.66019.490 19.407USD -3,493 22.37 Profit of 533 on sale
2025-07-30BUY24019.59020.640 20.535USD 4,928 22.41
2025-07-17SELL-12022.72023.065 23.031USD -2,764 22.47 Loss of -68 on sale
2025-07-11SELL-48821.63022.010 21.972USD -10,722 22.49 Profit of 252 on sale
2025-07-07BUY18320.17020.785 20.723USD 3,792 22.54
2025-07-02BUY3,35521.10021.890 21.811USD 73,176 22.58
2025-06-25BUY12022.80023.440 23.376USD 2,805 22.58
2025-06-20BUY1,06025.22025.580 25.544USD 27,077 22.55
2025-06-11BUY11423.28525.070 24.891USD 2,838 22.43
2025-06-10BUY11424.50024.745 24.721USD 2,818 22.42
2025-06-04SELL-5722.72023.765 23.660USD -1,349 22.38 Loss of -73 on sale
2025-04-23BUY5721.08021.625 21.570USD 1,230 23.13
2025-04-10SELL-45616.86017.300 17.256USD -7,869 23.77 Profit of 2,969 on sale
2025-04-08SELL-5716.30017.500 17.380USD -991 23.98 Profit of 376 on sale
2025-04-07SELL-5716.61017.060 17.015USD -970 24.10 Profit of 404 on sale
2025-04-04SELL-29016.42016.800 16.762USD -4,861 24.22 Profit of 2,163 on sale
2025-04-01BUY23218.03018.260 18.237USD 4,231 24.43
2025-03-31SELL-17418.49018.940 18.895USD -3,288 24.53 Profit of 980 on sale
2025-03-21BUY1,14919.52020.590 20.483USD 23,535 25.14
2025-03-14SELL-86421.00022.180 22.062USD -19,062 25.68 Profit of 3,123 on sale
2025-03-07SELL-10821.87022.240 22.203USD -2,398 26.10 Profit of 421 on sale
2025-03-04SELL-5421.95522.445 22.396USD -1,209 26.40 Profit of 216 on sale
2025-02-25BUY10825.23026.290 26.184USD 2,828 26.77
2025-02-19SELL-5427.11027.930 27.848USD -1,504 26.78 Loss of -58 on sale
2025-02-13BUY15926.85027.450 27.390USD 4,355 26.81
2025-02-12BUY5326.90027.140 27.116USD 1,437 26.81
2025-02-11BUY21226.90027.070 27.053USD 5,735 26.80
2025-01-17BUY21224.41025.490 25.382USD 5,381 25.72
2025-01-16BUY21224.48024.728 24.703USD 5,237 25.89
2025-01-10SELL-10624.88027.105 26.882USD -2,850 27.06 Profit of 19 on sale
2025-01-08SELL-21226.86027.340 27.292USD -5,786 27.47 Profit of 38 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of AVBP

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1954,109093,24658.0%
2025-09-1853,4940111,27648.1%
2025-09-1747,781065,92672.5%
2025-09-1638,333074,61151.4%
2025-09-1573,9860108,01568.5%
2025-09-1283,1690119,65569.5%
2025-09-11115,6770226,46551.1%
2025-09-1077,0250153,63750.1%
2025-09-0970,5530112,05463.0%
2025-09-0879,7290220,45036.2%
2025-09-0566,7550253,42426.3%
2025-09-0438,260074,19251.6%
2025-09-0331,976059,78653.5%
2025-09-02129,38020180,08271.8%
2025-08-2970,447082,51485.4%
2025-08-2853,254068,05078.3%
2025-08-27116,7050143,22081.5%
2025-08-2624,295434,40370.6%
2025-08-2534,071060,99255.9%
2025-08-2235,140085,62941.0%
2025-08-2120,146032,85361.3%
2025-08-2036,733266,49555.2%
2025-08-1959,304070,70783.9%
2025-08-1823,879040,39359.1%
2025-08-1540,664068,48859.4%
2025-08-14145,3850176,07382.6%
2025-08-13145,2900191,57775.8%
2025-08-12284,7910344,44882.7%
2025-08-11148,5030286,14551.9%
2025-08-0825,926043,63959.4%
2025-08-0739,380049,59579.4%
2025-08-0648,4903068,17771.1%
2025-08-0585,8450104,41282.2%
2025-08-0468,961088,43778.0%
2025-08-0195,73495118,08681.1%
2025-07-3194,2630111,25084.7%
2025-07-3083,0720119,14469.7%
2025-07-2973,478094,81377.5%
2025-07-2852,200063,22782.6%
2025-07-2542,644063,21667.5%
2025-07-2467,719074,69890.7%
2025-07-23116,7491,039172,96267.5%
2025-07-2272,088092,99177.5%
2025-07-2171,7450114,62862.6%
2025-07-1845,934079,30657.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy